Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemGenex licenses ground-breaking anticancer agent
The patented molecule, now called CXS299, is a platinum (IV) anticancer compound invented by professors in the department of experimental therapeutics at MD Anderson Cancer Center. CXS299 is
The patented molecule, now called CXS299, is a platinum (IV) anticancer compound invented by professors in the department of experimental therapeutics at MD Anderson Cancer Center. CXS299 is
Biodefense and Emerging Infections (BEI) Resources was established by the National Institute of Allergy and Infectious Diseases (NIAID) to acquire, authenticate, and produce reagents for scientists to carry
The projects will range from discovery to developmental stage programs and reach across multiple research sites of Pfizer’s Global R&D organization. Financial terms of the transaction include an
The formulations covered by the patent are applications of the company’s proprietary RapidMist drug delivery technology and are designed to deliver pain relief medications such as morphine and
The court ruled that the patents alleged to cover DDAVP (desmopressin acetate) are unenforceable and not infringed by Barr’s product. The court’s decision effectively ends the 30-month stay
The study, named DIAS2, will be a multinational, randomized, parallel-design dose-ranging study to confirm the results of earlier phase II studies. These studies demonstrated the potential of desmoteplase
The collaboration will focus on developing novel drug-device combinations incorporating RNAi therapeutics. RNAi, or RNA interference, refers to a technique for silencing targeted genes in a cell, inhibiting
Based on successful results of this pilot pharmacokinetic trial in healthy volunteers, Hana intends to file an investigational new drug (IND) application to commence an abbreviated clinical development
West received $7.1 million cash, approximately 14% of the stock of Archimedes Pharma, and a royalty interest in certain of Archimedes Pharma’s revenues in exchange for substantially all
ParinGenix is developing PGX-100 to ameliorate cardiac ischemia-reperfusion injury following myocardial infarction (heart attack), including both ST-elevated and non-Q-wave myocardial infarctions. Evaluation of PGX-100 in animal models shows